Late breaking abstracts: Therapies discovery and development
LB56 – LB59
- LB56: Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin (17-AAG) abrogates Akt activation and potentiates mTOR blockade in breast cancer cells
- LB57: Isolation of novel functional anti-cancer antibodies by phage display
- LB58: CRAd improve gene replication efficiency and cancer killing effect of E1-deleted adenovirus including killing gene in head and neck cancer cell line
- LB59: Interactions between RhoA-GTPase and cGMP/cAMP ignalling influence both the vascular disrupting and anti-angiogenic activities of combretastatin A-4-Phosphate
